title: Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
abstract: This study assessed the effects of rifapentine or rifampin on the pharmacokinetics of a single dose of bedaquiline and its M2 metabolite in healthy subjects using a two-period single-sequence design. In period 1, subjects received a single dose of bedaquiline (400 mg), followed by a 28-day washout. In period 2, subjects received either rifapentine (600 mg) or rifampin (600 mg) from day 20 to day 41, as well as a single bedaquiline dose (400 mg) on day 29. The pharmacokinetic profiles of bedaquiline and M2 were compared over 336 h after the administration of bedaquiline alone and in combination with steady-state rifapentine or rifampin. Coadministration of bedaquiline with rifapentine or rifampin resulted in lower bedaquiline exposures. The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for the maximum observed concentration (Cmax), area under the concentration-time curve to the last available concentration time point (AUC0-t), and AUC extrapolated to infinity (AUC0-inf) of bedaquiline were 62.19% (53.37 to 72.47), 42.79% (37.77 to 48.49), and 44.52% (40.12 to 49.39), respectively, when coadministered with rifapentine. Similarly, the GMRs and 90% CIs for the Cmax, AUC0-t, and AUC0-inf of bedaquiline were 60.24% (51.96 to 69.84), 41.36% (37.70 to 45.36), and 47.32% (41.49 to 53.97), respectively, when coadministered with rifampin. The Cmax, AUC0-t, and AUC0-inf of M2 were also altered when bedaquiline was coadministered with rifapentine or rifampin. Single doses of bedaquiline, administered alone or with multiple doses of rifapentine or rifampin, were well tolerated, with no safety concerns related to coadministration. Daily administration of rifapentine to patients with tuberculosis presents the same drug interaction challenges as rifampin and other rifamycins. Strong inducers of the cytochrome P450 isoenzyme CYP3A4 should be avoided when considering the use of bedaquiline. (This study is registered at clinicaltrials.gov under identifier NCT02216331.).
authors.affiliation: Global Alliance for TB Drug Development, New York, New York, USA.
authors.forename: Helen
authors.initials: H
authors.lastname: Winter
authors.affiliation: Global Alliance for TB Drug Development, New York, New York, USA.
authors.forename: Erica
authors.initials: E
authors.lastname: Egizi
authors.affiliation: Global Alliance for TB Drug Development, New York, New York, USA stephen.murray@tballiance.org.
authors.forename: Stephen
authors.initials: S
authors.lastname: Murray
authors.affiliation: Global Alliance for TB Drug Development, New York, New York, USA.
authors.forename: Ngozi
authors.initials: N
authors.lastname: Erondu
authors.affiliation: Global Alliance for TB Drug Development, New York, New York, USA.
authors.forename: Ann
authors.initials: A
authors.lastname: Ginsberg
authors.affiliation: RTI International, Research Triangle Park, North Carolina, USA.
authors.forename: Doris J
authors.initials: DJ
authors.lastname: Rouse
authors.affiliation: RTI International, Research Triangle Park, North Carolina, USA.
authors.forename: Diana
authors.initials: D
authors.lastname: Severynse-Stevens
authors.affiliation: RTI International, Research Triangle Park, North Carolina, USA.
authors.forename: Elliott
authors.initials: E
authors.lastname: Pauli
mesh_terms: D000328:Adult; D064687:Diarylquinolines / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: D064687:Diarylquinolines; C493870:bedaquiline; D012293:Rifampin; C018421:rifapentine